Premium
Myeloid cell‐derived IL‐6 in Chronic Lymphocytic Leukemia
Author(s) -
McManus Sheighlah Dallas,
Bertilaccio Maria Teresa Sabrina
Publication year - 2019
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2019.33.1_supplement.647.25
Subject(s) - chronic lymphocytic leukemia , immunology , myeloid , myeloid leukemia , immunotherapy , cancer research , medicine , tumor microenvironment , leukemia , biology , immune system
First‐line therapies, like chemo immunotherapy have limitation that lead patients to build resistance to mainstream treatments for chronic lymphocytic leukemia. Traditionally, the focus has been on leukemic cells. Conversely, little attention has been brought to the influence myeloid cells have on CLL progression. This study focused on the production of IL‐6 specifically by monocytes, macrophages, and myeloid‐derived suppressor cells (MDSCs) in the microenvironment of CLL cells. Experimentation revealed an increase of myeloid cell‐derived IL‐6 production in the peripheral blood and lymphoid tissues of Eμ‐TCL1 transgenic mice. Ultimately, these findings can be the basis for exploration of new treatments that target myeloid cells, and can be presented as an alternative for patients who have acquired a resistance to current therapies for CLL. Support or Funding Information SM was supported by the CPRIT Research Training Program RP170067 This study was supported by CLL Global Research Foundation (to MTSB) This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .